MORE FROM ALLERGAN AESTHETICS
Only BOTOX® Cosmetic can offer your patients The Look of 3—
a treatment of 3 areas, 64 units, at least 3 times a year*
*Treatments should be spaced at least 90 days apart.
Real patients treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.
*92% of patients (n = 342) report they discussed BOTOX® Cosmetic the first time they were treated. The majority of patients (85%; n = 314) are likely to continue using BOTOX® Cosmetic. Nearly 9 in 10 BOTOX® Cosmetic patients (n = 314) are willing to tell others about their treatment. Results from an online market research survey based on neurotoxin patients.5
is the one
PATIENTS ASK FOR5,*
COME BACK FOR5,*
TELL OTHERS ABOUT5,*
LET PRECISION BE YOUR DECISION
- accountability, quality, and state-of-the-art manufacturing, from start to finish -
- more publications, indications, and clinical research than any other neurotoxin -
PRECISE DOSING, REPEATABLE RESULTS1
- know what to expect, including simultaneous and repeat treatments -
*Over 30 years since the first FDA approval for therapeutic use in 1989.8
†Over 30 years of strict manufacturing standards to help ensure a quality product.9
Online and hands-on injector training to help you achieve desired patient outcomes and pursue clinical excellence.
Our professional loyalty program: The more products you purchase, the more rebates you'll receive.
Our patient loyalty program:Your patients can enjoy savings on select Allergan Aesthetics treatments.
BOTOX® COSMETIC ON INSTAGRAM®
REFERENCES: 1. BOTOX® Cosmetic Prescribing Information, July 2020. 2. Dysport® Prescribing Information, July 2020. 3. Xeomin® Prescribing Information, August 2020. 4. Jeuveau® Prescribing Information, January 2020. 5. Data on file, Allergan, 2016; Facial Injectables Neurotoxins Consumer A&U Tracker. 6. Data on file, Allergan, October 29, 2020; Westport Manufacturing Process. 7. BOTOX® Prescribing Information, February 2021. 8. Data on file, Allergan, March 2021, Botulinum Toxin Peer-Reviewed Publications. 9. Data on file, Allergan; FDA Product Approval Information.